These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 37264083)

  • 1. Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFR
    Saini R; Kumari S; Bhatnagar A; Singh A; Mishra A
    Sci Rep; 2023 Jun; 13(1):8885. PubMed ID: 37264083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors.
    Bhandari SV; Kuthe PV; Patil SM; Nagras OG; Sarkate AP; Chaudhari SY; Surve SV
    Chem Biodivers; 2023 Nov; 20(11):e202301081. PubMed ID: 37793119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
    Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA
    J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights.
    Suriya U; Mahalapbutr P; Wimonsong W; Yotphan S; Choowongkomon K; Rungrotmongkol T
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36558033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
    Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
    Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
    Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of luteolin -7-glucoside and epicatechin gallate from
    Maiti P; Nand M; Joshi T; Ramakrishnan MA; Chandra S
    J Biomol Struct Dyn; 2021 Sep; 39(14):5048-5057. PubMed ID: 32579072
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Patel HM; Ahmad I; Pawara R; Shaikh M; Surana S
    J Biomol Struct Dyn; 2021 Mar; 39(4):1491-1505. PubMed ID: 32102624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
    Patel H; Pawara R; Surana S
    Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Novel EGFR Inhibitors for the Targeted Therapy of Colorectal Cancer Using Pharmacophore Modelling, Docking, Molecular Dynamic Simulation and Biological Activity Prediction.
    Krishnan K A; Valavi SG; Joy A
    Anticancer Agents Med Chem; 2024; 24(4):263-279. PubMed ID: 38173208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational Computational Design of Fourth-Generation EGFR Inhibitors to Combat Drug-Resistant Non-Small Cell Lung Cancer.
    Park H; Jung HY; Kim K; Kim M; Hong S
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico target specific design of potential quinazoline-based anti-NSCLC agents.
    Mohammadnejadi E; Razzaghi-Asl N
    J Biomol Struct Dyn; 2023 Dec; 41(20):10725-10736. PubMed ID: 36826424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor.
    Ahmad I; Shaikh M; Surana S; Ghosh A; Patel H
    J Biomol Struct Dyn; 2022 Apr; 40(7):3046-3059. PubMed ID: 33174519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular docking and dynamics studies of 4-anilino quinazolines for epidermal growth factor receptor tyrosine kinase to find potent inhibitor.
    Muthuvel SK; Elumalai E; K G; K H
    J Recept Signal Transduct Res; 2018; 38(5-6):475-483. PubMed ID: 31038021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural alkaloids targeting EGFR in non-small cell lung cancer: Molecular docking and ADMET predictions.
    Saini N; Grewal AS; Lather V; Gahlawat SK
    Chem Biol Interact; 2022 May; 358():109901. PubMed ID: 35341731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
    Wang DD; Ma L; Wong MP; Lee VH; Yan H
    PLoS One; 2015; 10(5):e0128360. PubMed ID: 25993617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.
    Ashiru MA; Ogunyemi SO; Temionu OR; Ajibare AC; Cicero-Mfon NC; Ihekuna OA; Jagun MO; Abdulmumin L; Adisa QK; Asibor YE; Okorie CJ; Lawal MO; Babalola MO; Abdulrasaq IT; Salau LB; Olatunji IO; Bankole MA; Daud AB; Adeyemi AO
    J Mol Model; 2023 Apr; 29(5):128. PubMed ID: 37016200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of triple mutant T790M/C797S allosteric EGFR inhibitors: a computational approach.
    Karnik KS; Sarkate AP; Lokwani DK; Narula IS; Burra PVLS; Wakte PS
    J Biomol Struct Dyn; 2021 Sep; 39(15):5376-5398. PubMed ID: 32608331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study.
    Todsaporn D; Zubenko A; Kartsev V; Aiebchun T; Mahalapbutr P; Petrou A; Geronikaki A; Divaeva L; Chekrisheva V; Yildiz I; Choowongkomon K; Rungrotmongkol T
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
    Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
    Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.